John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLBR
1076
DELISTED
Colombier Acquisition Corp II
CLBR
| $3.85M | 0.01% |
+375,000
| New | +$3.82M |
|
1077
Terex
TEX
$7.53B
| $3.82M | 0.01% |
59,349
-170,705
| -74% | -$10M |
|
|
RAPT
1078
DELISTED
RAPT Therapeutics
RAPT
| $3.82M | 0.01% |
53,200
+49,120
| +1,204% | +$6.83M |
|
1079
Bank of Hawaii
BOH
$3.03B
| $3.8M | 0.01% |
60,899
+22,232
| +57% | +$1.41M |
|
|
BRFS
1080
DELISTED
BRF SA
BRFS
| $3.8M | 0.01% |
1,165,359
+483,439
| +71% | +$1.42M |
|
|
NVEI
1081
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
| $3.8M | 0.01% |
120,100
+81,300
| +210% | +$2.06M |
|
1082
CBRE Group
CBRE
$44B
| $3.79M | 0.01% |
+38,994
| New | +$3.5M |
|
1083
NovaGold Resources
NG
$4.1B
| $3.79M | 0.01% |
+1,263,384
| New | +$3.56M |
|
1084
Kura Oncology
KURA
$1.1B
| $3.79M | 0.01% |
+177,650
| New | +$3.45M |
|
|
SEE
1085
DELISTED
Sealed Air
SEE
| $3.78M | 0.01% |
101,591
+85,741
| +541% | +$3.07M |
|
1086
Natera
NTRA
$47.2B
| $3.77M | 0.01% |
41,201
-39,700
| -49% | -$2.99M |
|
1087
Alamo Group
ALG
$2.01B
| $3.77M | 0.01% |
16,499
-9,071
| -35% | -$1.9M |
|
1088
Cleveland-Cliffs
CLF
$6.45B
| $3.74M | 0.01% |
164,642
-3,565,664
| -96% | -$70.7M |
|
1089
Universal Technical Institute
UTI
$1.21B
| $3.72M | 0.01% |
233,383
+64,083
| +38% | +$930K |
|
|
HIMX
1090
Himax Technologies
HIMX
$2.34B
| $3.71M | 0.01% |
693,941
-225,900
| -25% | -$1.29M |
|
|
SHYF
1091
DELISTED
The Shyft Group
SHYF
| $3.71M | 0.01% |
298,361
-64,910
| -18% | -$724K |
|
1092
iShares Select Dividend ETF
DVY
$23.9B
| $3.7M | 0.01% |
30,009
-18,000
| -37% | -$2.11M |
|
|
MFA
1093
MFA Financial
MFA
$904M
| $3.68M | 0.01% |
322,720
+302,703
| +1,512% | +$3.39M |
|
1094
Factset
FDS
$10.9B
| $3.68M | 0.01% |
8,100
-18,628
| -70% | -$8.68M |
|
1095
PUT
PENN Entertainment
PENN
$2.45B
| $3.68M | 0.01% |
202,100
-307,900
| -60% | -$6.36M |
|
1096
Iron Mountain
IRM
$36.1B
| $3.68M | 0.01% |
+45,856
| New | +$3.32M |
|
1097
Ceco Environmental
CECO
$4.18B
| $3.66M | 0.01% |
158,920
-15,916
| -9% | -$328K |
|
1098
PUT
PureCycle Technologies
PCT
$1.33B
| $3.65M | 0.01% |
587,600
+25,000
| +4% | +$116K |
|
1099
Invesco S&P SmallCap 600 Revenue ETF
RWJ
$2.08B
| $3.65M | 0.01% |
85,225
-27,400
| -24% | -$1.12M |
|
1100
Cinemark Holdings
CNK
$4.45B
| $3.64M | 0.01% |
202,703
-329,395
| -62% | -$5.19M |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.